MALVERN, Pa. and SAN DIEGO, April 16, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced the closing of its underwritten public offering of 4,124,475 shares of its common stock, which includes the full exercise of the underwriters’ option to purchase an additional 537,975 shares, at a price to the public of $12.00 per share. The gross proceeds from the offering were $49.5 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by PhaseBio.